Identification of a novel mutation in ATP13A2 associated with a complicated form of hereditary spastic paraplegia

Yasuko Odake, MD, Kishin Koh, MD, PhD, Yoshihisa Takiyama, MD, PhD, Hiroyuki Ishiura, MD, PhD, Shoji Tsuji, MD, PhD, Masahito Yamada, MD, PhD, and Mitsuhiro Yoshita, MD, PhD

Neurol Genet 2020;6:e514. doi:10.1212/NXG.0000000000000514

Abstract

Objective
To establish molecular diagnosis for a family with a complicated form of autosomal recessive hereditary spastic paraplegia with intellectual disability, cognitive decline, psychosis, peripheral neuropathy, upward gaze palsy, and thin corpus callosum (TCC).

Methods
Physical examinations, laboratory tests, structural neuroimaging studies, and exome sequence analysis were carried out.

Results
The 3 patients exhibited intellectual disability and progressive intellectual decline accompanied by psychiatric symptoms. Gait difficulty with spasticity and pyramidal weakness appeared at the ages of 20s–30s. Brain MRI revealed TCC with atrophic changes in the frontotemporal lobes, caudate nuclei, and cerebellum. Exome sequence analysis revealed a novel homozygous c.2654C>A (p. Ala885Asp) variant in the ATP13A2, a gene responsible for a complicated form of hereditary spastic paraplegia (SPG78), Kufor-Rakeb syndrome, and neuronal ceroid lipofuscinosis. The predominant clinical presentations of the patients include progressive intellectual disability and gait difficulty with spasticity and pyramidal weakness, consistent with the diagnosis of SPG78. Of note, prominent psychiatric symptoms and extrapyramidal signs including rigidity, dystonia, and involuntary movements preceded the spastic paraparesis.

Conclusions
Our study further broadens the clinical spectrum associated with ATP13A2 mutations.
Hereditary spastic paraplegias (HSPs) are neurodegenerative disorders characterized by slowly progressing spasticity and pyramidal weakness of the lower limbs. Clinically, HSPs are classified into pure and complicated forms. Patients with pure HSPs show lower limb spasticity associated with pyramidal weakness alone, whereas patients with complicated forms show additional neurologic signs. To date, SPG1–SPG80 have been described as the genetic loci for HSP.

Mutations in the ATP13A2 gene were originally identified in patients with Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of juvenile-onset atypical parkinsonism associated with supranuclear gaze palsy, spasticity, and dementia, and subsequently reported in those with early onset Parkinson disease (PARK9), neuronal brain iron accumulation, and neuronal ceroid lipofuscinosis (CLN12). Recently, Estrada-Cuzcano et al. described cases of complicated HSP (SPG78) with c.2654C>A (p.Ala885Asp) in the ATP13A2 gene. Functional analysis of ATP13A2 showed the loss of function of ATP13A2.

We have recently experienced 3 sibling cases in one family with a complicated form of HSP accompanied by intellectual disability and psychiatric symptoms. Exome sequence analysis of the proband revealed a novel homozygous mutation of c.2654C>A (p.Ala885Asp) in the ATP13A2 gene. Functional analysis of ATP13A2 with the p.Ala885Asp missense variant confirmed the loss of function of ATP13A2.

Clinical manifestations of the 3 sibling cases

**Patient 1**
The pedigree chart of the family is presented in figure 1. The parents of the 3 siblings (patients 1, 2, and 3) were first cousins. Her father died of cerebral infarction at the age of 60 years, and her mother had dementia with anxiety along with lumbar spondylosis around the age of 76 years. Patient 1 (II-1) did not show any abnormalities at birth. Intellectual disability was noticed in her childhood and she went to a special support class. Her motor function, however, developed normally. At the age of 19 years, she experienced relationship and paranoid delusions, leading to the diagnosis of schizophrenia at a local general hospital. She was prescribed several antipsychotics. She developed a gait abnormality at the age of 29 years, and dystonia was observed in the extremities, especially in the upper extremities at the age of 30. There were neither cerebellar signs nor nystagmus. She was noticed to have rigidity in her extremities and supranuclear gaze palsy at the age of 33. Later, she exhibited spasticity in the lower limbs. Her intellectual impairment and gait disturbance gradually deteriorated, and she became bedridden around the age of 40. Partial seizures and generalized tonic seizures appeared around the age of 52. Later, she was diagnosed as having HSP at our hospital. She exhibited spasticity and muscle atrophy in the lower limbs, generalized increased tendon reflexes, extensor plantar reflexes, and involuntary movement in her upper trunk. Brain MRI taken at the age of 48 showed thin corpus callosum (TCC) and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem (figure 2A). Brain MRI did not show iron accumulation in the putamen or caudate nucleus. Routine blood test results were within the normal limits. There were no lesions in the spinal X rays. There was no hepatosplenomegaly.

**Patient 2**
Patient 2 was the younger sister of the patient 1. She had no abnormalities at birth. Intellectual disability was noticed in her childhood and she went to a special support class. Her motor function developed normally. At the age of 31, she talked to herself, exhibited forced laughing, and became increasingly irritable. She developed gait abnormality at the age of 32. She showed horizontal gaze nystagmus and rigid-akinetic clinical presentations but did not show tremor. She exhibited spasticity and muscle atrophy in the lower limbs, increased tendon reflexes in her 4 extremities, and extensor plantar reflexes. Her symptoms of intellectual impairment and gait disturbance gradually worsened, and she became bedridden at the age of 34. She was diagnosed as having HSP. At the age of 44, neurologic

![Figure 1 Pedigree chart of the family](Image)

Squares and circles indicate men and women, respectively. A diagonal line through a symbol indicates a deceased individual. Affected individuals are indicated by filled symbols. 1-2 had intellectual disability and gait disturbance at the age of 13 and died at age of 17.

Glossary

HSP = hereditary spastic paraplegia; KRS = Kufor-Rakeb syndrome; NBIA = neurodegeneration with brain iron accumulation; NPC = Niemann-Pick disease type C; PARK9 = Parkinson disease; SPG78 = spastic paraplegia; TCC = thin corpus callosum.
examination revealed severe intellectual disability and euphoria and an upward gaze limitation. She could not speak because of progressing dementia. She exhibited an involuntary movement of extending her right elbow, and her legs were in flexed positions with contracture of knee and ankle joints. She was diagnosed as having a complicated form of HSP. Brain MRI taken at the age of 46 showed TCC and atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem (figure 2B). Brain MRI did not show iron accumulation in the putamen or caudate nucleus. Routine blood test results were within the normal limits. There were no lesions in the spinal X rays. There was no hepatosplenomegaly.

She suffered from bacterial meningoencephalitis at the age of 46 but recovered by treatment with antibiotics. After this event, partial and generalized tonic seizures appeared. Later, she exhibited involuntary movement, shaking her head from side to side. Her condition gradually deteriorated, and she died of pneumonia at the age of 52.

**Patient 3**

Patient 3 was the youngest sister of patients 1 and 2. She had no abnormalities at birth. Intellectual disability was noticed in her childhood and she went to a special support class. Her motor function developed normally. At the age of 33, she experienced hallucinations and delusions. She presented with spastic tetraparesis and spastic gait at the age of 35. She became unable to walk in a few years. Her intellectual impairment deteriorated. At the age of 42, she had euphoria and exhibited dysarthria. She did not have any abnormal eye movements. She presented with spasticity and muscle atrophy in the lower limbs, generalized increased tendon reflexes, and extensor plantar reflexes. There was mild dysmetria in her upper limbs, and she exhibited stereotypic movements in her upper limbs and face. Owing to these movements, she frequently hit her arm against the bed fence. She was diagnosed as having a complicated form of HSP. Brain CT scan taken at the age of 45 showed atrophic changes in frontotemporal lobes, caudate nuclei, cerebellum, and brainstem (figure 2C). Routine blood test results were within normal limits. There were no lesions in the spinal X rays. There was no hepatosplenomegaly. Her condition gradually deteriorated and she died of respiratory failure at age 45.

**Mutational analysis**

We received approval from the National Hospital Organization, Hokuriku National Hospital Clinical Research Ethics
Committee, to conduct this study and obtained written informed consent from the family for genetic testing and protocol. Exome sequence analysis was performed as described previously.\textsuperscript{7}

NM 022089 was used as the reference sequence for \textit{ATP13A2} in this study. The disease-causing variant was confirmed by primer pairs (5\textsuperscript{'}-GCCACGCTGTCATCATTTCC and 5\textsuperscript{'}-GCCCAGCTGTCATCATTGG).

**Data availability**
The raw data are available upon request.

**Results**

**Identification of causative variant**
We searched exome sequence data of patient 1 for rare variants in the known causative genes for HSP (the gene list for HSP is shown in the supplementary data, links.lww.com/NXG/A319) and identified an apparently homozygous c.2654C>A (p.Ala885Asp) variant in \textit{ATP13A2} in patients 1 and 2 (figure 3A). Analysis of the number of reads from individual exons excluded the possibility of large deletions involving exons including exon 24 in one allele (figure 3C) confirming the homozygosity of the c.2654C>A (p.Ala885Asp) variant in the patients.

The variant was neither registered in gnomAD (gnomad.broadinstitute.org/) nor in the in-house database consisting of 1,261 control subjects. The variant was only registered in the integrative Japanese Genome Variation Database (ijgvd.megabank.tohoku.ac.jp/) at a very low allele frequency (0.00015). The amino acid, Ala, at codon 885 is evolutionally conserved among species (figure 3B).

In silico prediction revealed a combined annotation dependent depletion score of 28.1, supporting its pathogenicity (cadd.gs.washington.edu/home).\textsuperscript{9}
| Patient 1 | Patient 2 | Patient 3 | Patient 17 | Patient A | Patient B | Patient C |
|-----------|-----------|-----------|------------|-----------|-----------|-----------|
| HSP84/II-1 | HSP84/II-3 | HSP84/II-4 | HINH2 | NAPO-7 | | |
| c.[2654C>A];[2654C>A] | c.[2654C>A];[2654C>A] | Not examined | c.[1550C>T] (1550C>T) | c.[1550C>T] (1550C>T) | c.[364C>T];[364C>T] | c.[1349C>T];[1349C>T] |
| c.[1550C>T];[1550C>T] | c.[1550C>T];[1550C>T] | c.[364C>T];[364C>T] | c.[1349C>T];[1349C>T] | c.[1550C>T];[1550C>T] | c.[364C>T];[364C>T] | c.[1349C>T];[1349C>T] |
| c.1550C>T(;)(1550C>T) | c.1550C>T(;)(1550C>T) | c.1550C>T(;)(1550C>T) | c.1550C>T(;)(1550C>T) | c.1550C>T(;)(1550C>T) | c.1550C>T(;)(1550C>T) | c.1550C>T(;)(1550C>T) |
| c.364C>T(;)(364C>T) | c.1345C>T(;)(3418C>T) | c.2675G>A(;)(2675G>A) | c.2629G>A(;)(2629G>A) | c.insAAdelC(;) (24732474) | c.2126G>C(;)(2126G>C) | c.2159G>T(1) (2159G>T) |
| c.2159G>T(1) (2159G>T) | c.2159G>T(1) (2159G>T) | c.2159G>T(1) (2159G>T) | c.2159G>T(1) (2159G>T) | c.2159G>T(1) (2159G>T) | c.2159G>T(1) (2159G>T) | c.2159G>T(1) (2159G>T) |

- **Mutation (coding DNA)**
  - Estrada-Cuzcano et al.
  - van de Warrenburg et al.
  - Erro et al.
  - Estiar et al.

- **Mutation (predicted protein)**
  - p.(Ala885Asp)
  - p.(Thr517Ile)
  - p.(Thr517Ile)
  - p.(Thr517Ile)
  - p.(Gln122*)
  - p.(Gln122*)
  - p.(Arg449*)
  - p.(Arg449*)
  - p.(Gly892Asp)
  - p.(Gly892Asp)
  - p.(Gly877Arg)
  - p.(Gly877Arg)

| Gender | Female | Female | Female | Male | Male | Male | Female | Male | Male | Female | Male | Male | Male |
|--------|--------|--------|--------|------|------|------|--------|------|------|--------|------|------|------|
| Age at onset of psychiatric symptom (y) | 19 | 30 | 33 | n.a. | n.a. | n.a. | None | 40 | 31 | 12 |
| Age at onset of gait difficulty (y) | 29 | 30 | 35 | 30 | 33 | 30 | 36 | 32 | 11 | 31 | 31 | 18 | 32 |
| Age at examination (y) | 49 | 45 | 42 | 50 | 40 | 50 | 47 | 39 | 37 | n.a. | 44 | 31 | 32 |
| Cognitive deficits | Intellectual disability, severe dementia | Intellectual disability, severe dementia | Intellectual disability, severe dementia | Slight verbal memory deficit | None | Slight verbal memory deficit | Severe dementia | Severe frontaltemporal dementia | Cognitive decline | Intellectual disability | Cognitive decline | Mild intellectual disability, cognitive decline | Learning difficulty |
| Behavioral and psychiatric symptoms | Delusion | Irritability, empty smile | Hallucination, delusion | None | None | None | Labile motivation | Aggression | acoustic hallucinations | None | None | Laughing excessively, aggressive | Delusion, hallucination | Psychotic episode, paranoid delusions |
| Pyramidal and peripheral motor system | UL/LL spasticity | + | + | + | + | + | + | + | + | + | + | + | + |
| UL/LL weakness | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Increased tendon reflexes UL/LL | + | + | + | + | + | + | + | + | + | + | + | + | n.a. |
| Muscle atrophy | + | + | + | + | + | + | + | + | + | + | + | + | n.a. |
| Babinski sign | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Extensor |
| Extapyramidal motor system | + | + | + | + | + | + | + | + | + | + | + | + | n.a. |
| Other involuntary movement | (upper body) | (head) | (head) | (head) | (head) | (head) | (head) | (head) | (head) | (head) | (head) | (head) | (head) |
| Supranuclear palsy | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure | Partial and generalized tonic seizure |

Continued
Discussion

The clinical presentations of the 3 patients are summarized in Table. Prominent psychiatric symptoms preceding gait abnormality commonly observed in the 3 patients in this family was one of the characteristic clinical presentations. In particular, all the patients presented psychiatric symptoms such as hallucination, delusion, or increased irritability over one to 10 years before the onset of gait disturbance. Although psychiatric symptoms have previously been frequently reported in patients with KRS or PARK9, they usually develop several years after the onset of gait disturbances or administration of antiparkinsonian drugs. Among the patients with PARK9, the one patient reported by Schneider et al.4 is an exceptional case presenting with the psychiatric symptoms before the onset of parkinsonism. Among the patients with the clinical diagnosis of HSP with ATP13A2 mutation (SPG78), only one case of Estiar et al.12 presented with psychiatric symptoms preceding spastic paraparesis.

Psychiatric symptom is also observed in patients with neurodegeneration with brain iron accumulation (NBIA) presenting with progressive dystonia/parkinsonism.15,16 Although we did not observe iron deposition in our patients, NBIA or NBIA-related diseases should also be included in a differential diagnosis for patients presenting with psychiatric symptoms accompanied by dystonia/parkinsonism. Supranuclear gaze palsy is also a characteristic finding in ATP13A2-related diseases. In addition to progressive supranuclear palsy and parkinsonism linked to chromosome 17 (FTDP-17), supranuclear gaze palsy is also observed in patients with Niemann-Pick disease type C (NPC) presenting with dystonia, cognitive decline, and psychiatric symptoms,17–19 thus NPC should also be included in a differential diagnosis.

TCC is an important finding in the differential diagnosis of HSP and is observed in SPG1, SPG11, SPG15, SPG21, SPG44, SPG46, SPG47, SPG49, SPG50, SPG54, SPG63, SPG66, and SPG71.20 Because MRI scans revealed TCC in patients 1 and 2 in this study and one patient with SPG78 showed TCC,6 SPG78 should also be included in the differential diagnosis of HSPs with TCC.

Patient 1 initially manifested extrapyramidal symptoms. Indeed, she was initially tested for possible Wilson disease, but spastic paraparesis appeared later and became predominant over time. Patient 2 had pallidopyramidal syndrome (rigidokinetic plus spasticity), and patient 3 had spastic tetraparesis with cognitive decline. In contrast to previous reports showing the similar clinical presentations among the siblings with the ATP13A2 variants,6 the 3 siblings in this family exhibited similar but considerable variation in the complex clinical presentations. Thus, the present 3 sibling case falls in the continuum between the 2 extremities (HSP78 and KRS).6,21 Intrafamilial and interfamilial variations in the clinical presentations associated with ATP13A2 mutation should be further investigated.
Study funding
This work was supported by Grants-in-Aid from the Research Committee for Ataxic Disease (Y. Takiyama), the Ministry of Health, Labor and Welfare, Japan, JSPS JP18K07495 (Y. Takiyama) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, and grants for AMED under Grant Number JP 17ek0109078 (Y. Takiyama), 19ek0109279 (S. Tsuji), and 18kk0205001 (S. Tsuji).

Disclosure
The authors report no disclosures. Go to Neurology.org/NG for full disclosures.

Publication history
Received by Neurology: Genetics March 30, 2020. Accepted in final form August 7, 2020.

Appendix Authors

| Name              | Location                                                                 | Contribution                                |
|-------------------|---------------------------------------------------------------------------|---------------------------------------------|
| Yasuko Odake, MD  | Department of Clinical Research, National Hospital Organization, Hokuriku National Hospital, Nanto, Japan | Drafting of the manuscript and clinical characterization |
| Kishin Koh, MD, PhD| Department of Neurology, Graduate School of Medical Science, University of Yamanashi, Yuyo, Japan                  | Genetic tests, assessment and revision of the manuscript |
| Yoshihisa Takiyama, MD, PhD | Department of Neurology, Graduate School of Medical Science, University of Yamanashi, Yuyo, Japan | Genetic tests, assessment and revision of the manuscript |
| Hiroyuki Ishiura, MD, PhD | The University of Tokyo, Tokyo, Japan                                   | Genetic tests, assessment, major role in the acquisition of data and revision of the manuscript |
| Shoji Tsuji, MD, PhD | Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Institute of Medical Genomics, International University of Health and Welfare | Genetic tests, assessment, major role in the acquisition of data and revision of the manuscript |
| Masahito Yamada, MD, PhD | Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan | Clinical characterization and revision of the manuscript |

Appendix (continued)

| Name          | Location                                                                 | Contribution                                |
|---------------|---------------------------------------------------------------------------|---------------------------------------------|
| Mitsuhiro Yoshita, MD, PhD | Department of Clinical Research, National Hospital Organization, Hokuriku National Hospital, Nanto, Japan | Clinical characterization, revision of the manuscript, study supervision and coordination |

References
1. Najim al-Din AS, Wriekat A, Mubaidin A, et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994;99:347–352.
2. Di Fonzo A, Chien HF, Socal M, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007;68:1557–1562.
3. Ning YP, Kanai K, Tomiyama H, et al. Park9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 2008;70:1491–1493.
4. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Movement Disord 2010;25:979–984.
5. Bras J, Verloes A, Schneider SA, Mole SE, Guerreiro RJ. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 2012;21:2466–2460.
6. Estrada-Cucuzano A, Martin S, Chamova T, et al. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). Brain 2017;140:287–305.
7. Miyahoshi T, Ochiai T, Suzuki N, et al. A novel homozygous mutation of the TFG gene in a patient with early onset spastic paraplegia and later onset sensorimotor polyneuropathy. J Hum Genet 2019;64:171–176.
8. Santoro L, Breedveld GJ, Manganelli F, et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011;12:33–39.
9. van de Warrenburg BP, Schouten MI, de Bot ST, et al. Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and unanticipated rare disorders. Eur J Hum Genet 2016;24:1460–1466.
10. de Bot S, Kamsteeg EJ, Van De Warrenburg BPC. Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what’s in a name? Brain 2017;140:e73.
11. Erro R, Picillo M, Manara R, et al. From PARK9 to SPG78: the clinical spectrum of ATP13A2 mutations. Parkinsonism Relat Disord 2019;65:272–273.
12. Estiar MA, Lev Belle E, Spiegelman D, et al. Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype. Mol Gen Genom Med 2019;7:e1052.
13. Williams DR, Hadeed A, al-Din AS, et al. Kufor-Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Movement Disord 2005;20:1264–1271.
14. Elberg H, Hansen L, Korbo L, et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clin Genet 2012;82:256–263.
15. Diaz N. Late onset atypical pantotethenate-kinase-associated neurodegeneration. Case Rep Neurol Med 2013;2013:860210.
16. Attademo L, Paolini E, Bernardini F, Quartenzi R, Moretti P. Adult-onset case of undiagnosed neurodegeneration with brain iron accumulation with psychiatric symptoms. Case Rep Psychiatry 2014;2014:742042.
17. Nadjar Y, Hütter-Moncada AI, Latour P, et al. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis 2018;13:1–12.
18. Abela L, Plecko B, Palla A, et al. Early co-occurrence of a neurologic-psychiatric disease pattern in Niemann-Pick type C disease: a retrospective Swiss cohort study. Orphanet J Rare Dis 2014;9:1–9.
19. Lee SY, Lee HJ, Kim SH, et al. Two siblings with adolescent/adult onset niemann-pick disease type C in korea. J Korean Med Sci 2016;31:1168–1172.
20. de Souza PV, de Rezende Pinto WBV, de Rezende Batistella GN, et al. Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum 2017;16:525–551.
21. Schüle R. Reply: complicated hereditary spastic paraplegia due to ATP13A2 mutations: what’s in a name? Brain 2017;140:e74.
Identification of a novel mutation in ATP13A2 associated with a complicated form of hereditary spastic paraplegia
Yasuko Odake, Kishin Koh, Yoshihisa Takiyama, et al.
Neurol Genet 2020;6;
DOI 10.1212/NXG.0000000000000514

This information is current as of September 8, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://ng.neurology.org/content/6/5/e514.full.html

References
This article cites 21 articles, 0 of which you can access for free at:
http://ng.neurology.org/content/6/5/e514.full.html##ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://ng.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://ng.neurology.org/misc/addir.xhtml#reprintsus